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Stereotactic body radiation therapy (SBRT) is delivered in a curative intent to many primary
and  secondary tumors.
Concerning liver metastasis, SBRT can be safely delivered using one to five fractions. An
excellent local control is obtained with doses from 20 to 60 Gy. For primary hepatic tumors,
results are also good, but the risk of hepatic toxicity related to liver pre-existent pathology
must  be taken into account. Radiation induced liver disease (RILD) is not frequent in its clas-
sical  presentation, but modifications of liver enzymes are often observed. Other toxicities
of  SBRT on the duodenum, small bowel and biliary tract are also described. With respect





and  takes place among curative treatment of liver tumors, as surgery, radiofrequency and
embolization.
©  2017 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved.
SBRT provides high doses per fraction, delivered daily or every
3–61.  Background
Stereotactic body radiation therapy (SBRT) is defined as an
ablative irradiation modality, the most often delivered in less
than 5 fractions, taking into account positioning uncertainties
and breathing motions with image-guided radiation therapy
(IGRT). Liver SBRT aims to treat hepatic metastasis in a cura-
tive intent as surgery and radiofrequency. Primary liver tumors
also benefit from SBRT either exclusively or as a bridge to
transplantation.1,2
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1507-1367/© 2017 Greater Poland Cancer Centre. Published by Elsevier To obtain a favorable therapeutic index, irradiation sched-
ule and targeting have to be strictly evaluated. Efficient doses
on tumor must be defined, as well as tolerable doses on healthy
liver and other critical structures.
2.  Dose  prescription  and  treatment  issuessecond day. The number of fractions vary from one to six,
with most authors treating liver with 3–5 fractions. Table 1
Sp. z o.o. All rights reserved.
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Table 1 – Prescription, local control and toxicity from selected series.
Sample Dose Prescription Local control Toxicity > = grade 3
Blomgren et al.
(1995)
14  pts with mets 7 Gy–45 Gy ICRU point 50% response
rate
1  hemorragic gastritis
Herfarth et al.
(2004)










63  mets 3 × 12 Gy
To




92% at 2 years
100% for
tumors < 3 cm
DLT not reached
Wulf et al. (2006) 39 pts with mets
5 with
HCC
3  × 10 Gy
3 × 12.5 Gy
1 × 26 Gy
65% isodose 100% HCC last
follow up




34  pts with mets
11 with HCC
3  × 12.5 Gy
At risk patients
5 × 5 Gy
65%  isodose line 84% 2 years 1 classic RILD (liver failure and
fatal infection, pt Child B
initial)
1 portal hypertension with
melena
2 elevation GGT Grade3
Hoyer et al. (2006) 44 pts with mets 3 × 15 Gy Isocenter 79% 24 mths One lethal hepatic failure






3  × 10 Gy to












Max in PTV 140%
71% 1 year Grade 5 SBO + grade 4 bleed
(progression)
SBO abdominal hernia
Grade 3 gastritis/oesophagitis 2
Rusthoven et al.
(2009)
47  pts with 63
mets






5  IHC and CHC















87% 1 year No toxicity
Tse et al. (2008) 47HCC IHC 6 × 9-–0 Gy Unspecified 65% 1 year 10 Grade 3 liver enzymes
1 bleeding from tumor
duodenal connection (lethal)
1 SBO (lethal)
CTP progression A-B 7/41
Andolino et al.
(2011)
60  HCC 3 × 14 (CTP)A
5 × 8 (CTP B)
80% isodose 90% 2 years 20% progression CTP class




61  pts with mets
71 lesions
3  × 25 Gy Mean dose
(VMAT)
94% 12 mths 1 grade 3 chest wall pain
Bujold et al.
(2013)
10 HCC 6 × 4 Gy
To 6 × 9 Gy





3  × 15 Gy
Cyberknife





















Mets: metastasis VMAT: volumetric modulated arc therapy
Pts: patients Fns: fractions
HCC: hepatocellular carcinoma
IHC: intra hepatic cholangiocarcinoma
CTP class: Child Turcotte Pugh class
SBO: small bowel obstruction
Fx: fractions
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synthesizes the data from different studies in terms of radio-
therapy planning, local control, and toxicity.
The first reported studies used doses extrapolated from
conventional radiotherapy.7–9 Then, prospective trials were
conducted taking into account radiobiological parameters and
following dose escalation protocols.10,11
Dose to the target is most often defined on the prescription
isodose surrounding the PTV, which varies from 65 to 90%,
and sometime on the isocenter.7,12 Using intensity modulated
radiation therapy (IMRT), the dose is prescribed to the mean
dose in the PTV, and is less heterogeneous.6
From a radiobiological point of view, the question of
whether a classic radiobiological modeling, with the linear-
quadratic (LQ) model, is appropriate for large doses per
fraction remains debated. For Kirkpatrick,13 the underlying
mechanisms implied by the LQ model do not reflect the vas-
cular and stromal damages produced at the high doses per
fraction encountered in radiosurgery, and ignore the impact
of radioresistant subpopulations of cells. It has been hypoth-
esized that SBRT may cause significant vascular damage in
tumors, leading to indirect cell death.14 Anyway, a recent
review15 concluded that “the available preclinical and clinical
data do not support a need to change the LQ”. The possibility
of additional biological effects resulting from endothelial cell
damage or enhanced tumor immunity is also discussed, as is
the increased importance of tumor hypoxia in tumor response
to SBRT.16
Main factors to impact the local control are the dose deliv-
ered, the target volume and the tumor type.
2.1.  Dose
The dose delivered is the most important factor affecting local
control. Prospective trials with dose escalation demonstrate
this dose effect relation.10,17–22,43
Andratschke10 treated 71 patients with 91 metasta-
sis (mets). Treatment consisted of 3–5 fractions with
5–12.5 Gy/fraction prescribed to the surrounding 60–95% iso-
dose. Median local recurrence-free interval was 23 months
with a local control rate of 74.7%, 48.3% and 48.3% after 1, 2
and 3 years, respectively. Only minimum biologically effec-
tive dose (BED) to gross tumor volume (GTV) remained as an
independent significant factor for local control in multivari-
ate analysis. No local recurrences were observed in lesions
(n = 12) which received a minimal BED to the GTV of 120 Gy
(alpha/beta = 10).
McCammon et al.18 reported the data of 141 consecutive
patients with 246 pulmonary or hepatic lesions (65 primaries,
181 metastasis) treated with three-fraction SBRT from Oct.
1999 through Aug. 2005. On univariate analysis, increased
dose (either nominal or Equivalent Uniform Dose (EUD) and
smaller Gross Tumor Volume were significant predictors of
higher local control). Lesions treated to a nominal dose of
54 Gy or greater had a 3-year actuarial local control rate
of 89.3% compared with 59.0% and 8.1% for those treated
to 36–53.9 Gy and less than 36 Gy. On multivariate analysis,
only increased nominal dose and EUD retained statistical
significance.
Information resumed in Table 1 show that primitive or sec-
ondary hepatic tumors can be treated with SBRT as an ablativediotherapy 2 2 ( 2 0 1 7 ) 96–102
treatment with a local control higher than 75% at the end of
the first year after treatment. The dose required for a favor-
able result of the radiotherapy treatment might be 24–30 Gy in
a single dose, 45–60 Gy in 3 fractions, 40–50 Gy in 5 fractions,
48–60 Gy in 6 fractions.1,10,18,23,24
2.2.  Volume  of  the  tumor  (Gross  Tumor  Volume  GTV)
In most articles, a tumor volume appears as an inde-
pendent factor predictive of the local control of a tumor
treated with SBRT.3,18,25,26 Lee et al.25 describes the out-
come of SBRT for hepatic metastasis from different origins,
the local control is related to tumor volume with a 75 ml
threshold.
On the other hand, Rusthoven et al.26 analyzing the out-
come of 63 secondary lesions treated with SBRT in 47 patients
shows that the 2-year LC was 100% for mets smaller than 3 cm
compared with 77% (95% CI, 43%–92.2%) for lesions greater
than 3 cm.
2.3.  Effectiveness  compared  between  primary  and
mets
Most of the studies concern metastasis only or primary tumors
only but some series included a mix  of metastasis and pri-
maries. By performing analysis on primary tumors (HCC,
IHC) and mets, these studies allow to analyze the outcomes
and toxicities of these 2 populations treated with the same
protocol.4,18,20,27 The differences observed between metasta-
sis and HCC in term of toxicity of treatments and survival
is related to hepatic comorbidities (cirrhosis) rather than
tumor radiosensitivity. Local control at one year is similar
between the two populations. For example, Wulf observed
a 100% local control of HCC at 15 months vs. 92% for
metastasis.
This is confirmed by the results observed in specific
CHC studies9,28 with local controls around 80% at one year.
Cholangiocarcinoma is a bad prognosis primary liver tumor
presenting a low sensitivity to conventional radiotherapy even
when associated with chemotherapy. It is interesting to note
that in Tse’s article,28 the 10 patients presenting a cholan-
giocarcinoma responded to the SBRT as well as HC. In the
same way, Barney et al.11 present a population of 10 cholan-
giocarcinomas irradiated on primary site, the recurrence or a
metastasis at a dose between 45 and 60 Gy in 3–5 fractions with
a 100% local control but with distant recurrence in the liver in
four patients.
2.4.  Other  prognostic  factors
12Hoyer et al. describes other prognostic factors related to
improved local control including smaller tumor volumes,
potentially non-CRC metastases, metachronous liver metas-
tases and absence of previous chemotherapy.
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Table 2 – Dose-volume constraints for organs at risk with Biologic Equivalent Dose (BED) from selected studies.










D30 < 7 Gy/D50 < 5 Gy
V21 < 33%
V15 < 50%
V60  < 30%
V29.3 < 50%
3 fx V12.4 < 30%/V7.8 < 50%




D100  < 7 Gy
D5 cc < 21 Gy
V30 < 0.5 cc
1  fx 13.1 Gy max/3 fx 9 Gy
max
3 fx V39 < 5 cc/5 fx V32 < 5 cc
V 48.8 < 0.5 cc





D100 < 7 Gy
D5 cc < 21 Gy
V30 < 0.5 cc
30  Gy max
1 fx 13.1 Gy max/3 fx 9 Gy
max
3 fx V39.4 < 5 cc/5 fx
V32 < 5 cc
V 48.8 < 0.5 cc




12  Gy max
D100 < 7 Gy
D5 cc < 21 Gy
V30 < 0.5 cc
40.8  Gy max
1 fx1 6.8 Gy max/3 fx10.3 Gy
max
3 fx V50.5 < 5 cc/5 fx
V38.6 < 5 cc
Spinal cord (alpha/beta 3) Schefter (2005)
Hoyer (2006)
Mendez Romero
18  Gy max
18 Gy max
15 Gy max
54  Gy max
54 Gy max





























.  Doses  to  organs  at  risk  and  toxicity
Table  2)
.1.  Liver
.1.1.  Hepatic  toxicity
he main organ at risk for irradiation of hepatic tumors is
he liver itself.29,30 Radiation-induced liver disease (RILD) is
he main radiotherapy toxicity.29,31–33 Hepatic lesions have the
haracter of veno-occlusive diseases (VOD). For classical RILD,
ymptoms occur 4 weeks after hepatic irradiation, with an
ncreased weight, a fatigue, a non-icteric ascitis and a predom-
nant increase of PALK. In general, the radiologic presentation
n CT scan is a hypodensity which disappears a few months
ater.3,20 In contrast, patients with a pre-existent hepatopathy,
s cirrhosis or viral hepatitis, may present a transaminases
ncrease and a jaundice within three months following hepatic
rradiation corresponding to a non-classical post-radiation-
epatopathy.
.1.1.1.  Hepatic  functions  and  tumor  type..  Classical data show
hat the whole healthy liver can receive 30 Gy per fractions
f 2 Gy34 and has the feature of a parallel structured organ
rom a radiobiological point of view.29,31 The comparison
f studies should take into account the treatment duration
nd the doses per fraction according to the quadratic lin-
ar model.31,35–37 The alpha/beta ratio for healthy liver is
uite low, from 1.513 to 338. Murphy et al.33 postulates that
he risk of hepatic toxicity for hypofractionated irradiation isV27 < 0.5 cc max
V67.5 < 0.5 cc
overestimated in clinical practice when biological normaliza-
tion is omitted. While analyzing 2O3 patients treated with
conformational RT and intra-hepatic chemotherapy, Dawson
et al.39 showed in 2002 that the radiation-induced liver disease
(RILD) threshold dose is 30 Gy, the 5% risk of RILD corre-
sponding to a 32 Gy dose (2 Gy/fraction) for patients carrying
metastasis and 28 Gy for primary hepatic tumors.40 Andolino
et al.41 described a population of 60 patients treated from
2006 to 2009 for HCC associated with an A (36 patients) or B
(24 patients) Child–Turcotte Pugh (CTP) score cirrhosis. Four
patients out of the 8 patients with a CTP B score higher than
8, developed a hepatic failure during or immediately follow-
ing the treatment. In this center, the indications of liver SBRT
for this population are actually restricted to being a bridge for
transplantation. For the other patients, it is proposed to limit
the SBRT indications to patients with an A or B CTP score lower
than or equal to 7 with a maximum tumor diameter lower than
6 cm and one to three lesions to be treated.
Taking these data into account, Pan et al.31 proposed con-
straints for prescription on the liver minus  GTV volume for
non-uniform irradiation on healthy and pathological liver. For
3 fractions treatment: less than 15 Gy for metastasis, less than
13 Gy for HCC and less than 6 Gy for HCC with a CPT equal to
or lower than B. In terms of critical volume, 700 ml  of healthy
liver should receive less than 15 Gy.3.1.2.  Biliary  tract  toxicity
Few papers are dedicated to biliary complications of SBRT.
Eriguchi et al.42 studied 50 patients irradiated on the central
nd ra100  reports of practical oncology a
biliary tract in 5 fractions for hepatic tumors at a total dose
of 50 Gy for metastasis, 40 Gy for Child A HCC and 35 Gy for
Child B HCC. The delineation of biliary tract was standard-
ized and the dose volume histograms (DVH) of the biliary
ducts were normalized for the length of the biliary duct irra-
diated. In this study, 2 grade I biliary stenosis occurred, one
patient having received more  than 20 Gy on 7 mm of the bil-
iary duct presented a asymptomatic stenosis while the other
one was treated twice and received more  than 80 Gy on 13 mm
of the left hepatic duct. The 7 patients who received more
than 20 Gy on the gallbladder did not present any toxicity.
In another article, Osmundson et al.37 presented a popula-
tion of 96 patients irradiated for primary or metastatic hepatic
lesions treated between 2006 and 2013. The central biliary sys-
tem was defined by the authors as a 15 mm expansion of the
portal veina from the splenic convergence to the portal bifur-
cation. Fifty-one patients presented biliary or hepatic tumors
and 45 metastasis. The median fraction number was 5 and
51% of patients received three fractions. Sixty-seven percent
of patients had a Child A score, 28.1% a B score. Hepatobi-
liary grade 2 toxicities were observed for 23 patients (24%)
and grade 3 toxicities for 18 patients (18.8%). The most fre-
quent grade 3 toxicities were stenosis or biliary obstruction,
the frequency being 20 fold higher for patients with cholan-
giocarcinoma (CCA). Two deaths related to biliary obstruction
were observed, one of them for a patient with cholangiocar-
cinoma. The predictive factors in a univariate analysis were
the cholangiocarcinoma and HCC histology, the presence of
a stent during treatment and dosimetric factors. In a multi-
variate analysis, VBED10 72 > 21 cc, VBED66 > 24 cc and a mean
equivalent dose > 14 Gy on the central biliary hepatic tract
were correlated with a toxicity risk > 3, as well as CCA histology
and the presence of the stent. The authors propose 3 fractions
treatment with the following constraints on the central biliary
tract: VBED10 72 < 21 cc and a VBED66 < 24 cc.37
3.1.3.  Stomach,  duodenal  and  bowel  toxicities
The toxicity on the digestive tube is the one most frequently
observed with hepatic SBRT. In general, these side effects are
limited to a limited and transient bleeding, but some severe
hemorrhages have been observed as well as perforations.
Some data on duodenal SBRT toxicities have been identified
with pancreatic tumor SBRT studies. In terms of radiobiology,
the signification of doses is different for stomach (alpha/beta
5) and for bowel (alpha/beta 8).1 For stomach, the proposed
constraints in various studies range from 7 to 30 Gy maximum
dose with a BED of 10.3–90 Gy5.1,3,4,17,28 Mendez Romero et al.
constrained 5 cc of stomach to less than 21 Gy.20 A few gas-
tric acute toxicities have been reported. Kopek43 describes an
acute gastric toxicity with two grade 3 nausea for 44 patients.
Herfarth et al.3 also describes nausea and anorexia for 11
patients on the 37 accrued. Wulf et al.4 proposes a prophy-
lactic IPP or anti-H2 treatment during treatment of hepatic
metastasis closed to the stomach.
Hoyer et al.44 in a population of 22 patients receiving 45 Gy
in 3 fractions delivered in 5–10 days for non operable pancre-
atic tumor whose size was higher than 6 cm,  evaluated toxicity
for the duodenum. Seventy-nine percent of the patients pre-
sented an acute toxicity, four patients (18%) developed a severe
mucositis or a duodenal or gastric ulceration and one of themdiotherapy 2 2 ( 2 0 1 7 ) 96–102
developed a perforation. In this study, the median volume
receiving more  than 30 Gy was 136 ml.  In another work, the
same team12 analyzed a population of 64 patients with 141
hepatic metastasis from colorectal carcinoma. They received
3 fractions of 15 Gy delivered in 8 days. Two patients who
received more  than 30 Gy on the duodenum presented ulcera-
tions with a favorable issue with medical treatment. One grade
3 toxicity among 15 diarrheas was reported in this study.23
For pancreatic tumor stereotaxy, Murphy et al.33 have pro-
posed a dosimetric model of duodenal toxicity. The duodenal
delineation was specified with precision for 73 patients irradi-
ated with a single 25 Gy dose 14 days after the last Gemcitabine
treatment administration. Twelve patients presented grade
2–4 duodenal toxicities with a median interval of 6.3 months.
The predictive dosimetric parameters were a V15 < 9.1 cc, a
V20 < 3.3 cc and a Dmax > 23 Gy. Applying the same prescrip-
tion to 27 cholangiocarcinoma, Kopek et al.43 observed 22%
of gastric or duodenal ulcerations after a median delay of
6.7 months requiring hospitalization and blood transfusion, a
duodenal stenosis for 4 patients (11%), two of them requiring
dilatation. The probability of grade higher or equal to 2 ulcer-
ation was correlated to the maximal dose delivered to 1 cc of
the duodenum. The constraint followed by this group is one
cc of the duodenum to get no more  than 21 Gy in 3 fractions
(V21Gy < 1 cc).
Bae et al.45 evaluated the abdominal or pelvic SBRT toxi-
cities delivering 33–60 Gy in three fractions for 202 patients.
The grade 3 toxicity on the digestive tract was highly corre-
lated to the V25 and to the overall time treatment. The severe
bowel toxicity decreases from 50% to 4% when the V25 value is
respectively higher or lower than 20 ml.  In the same way, the
grade 3 toxicity raised from 0 to 18% for an overall treatment
time decreased from 8 to 4 days.
For small bowel, multiple proposals of limiting constraints
have been defined in different studies: 12 Gy maximum,3 30 Gy
maximum,17,22 D100 < 7 Gy,4 D5 < 21 Gy,46 V30 < 0.5 cc.47 How-
ever, no major toxicity has been reported.
3.1.3.1.  Chest  wall.  As observed using lung SBRT, chest wall
pains and sometimes rib fracture are observed after liver SBRT.
They are of course more  frequent after treating tumors close
to the chest wall, and for doses above 50 Gy. Andolino et al.38
proposes a Dmax less than 50 Gy and that less than 5 cc of
the chest wall receive 40 Gy, if these objectives are compatible
with adequate tumor coverage.
3.1.4.  Less  exposed  organs  at  risk
Dose limitation proposals have also been formulated for less
exposed organs at risk, and observing these constraints, no
clinical toxicity have been documented.
Esophagus
A death due to bleeding on oesophageal varices, probably
linked to cirrhosis without any other oesophageal toxicity, has
been observed.46
Some liver SBRT protocols define constraints for esopha-
gus. Méndez Romero et al.46 limits to 5 cc the oesophageal
volume receiving more  than 21 Gy in 3–5 fractions.
A maximal dose of 14 Gy is proposed by Herfarth et al.,3 and
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Wulf et al.4 proposed to limit the dose delivered to the
earth to 7 Gy and Tse et al.28 proposed a V40 < 0.5 cc. No car-
iac toxicity has been described.
Kydney
Constraints proposed for the two kidneys are V15 lower
han 35%, and for the right kidney lower than 33%.17,22,46
Spinal cord
The dose has to be restricted to 18 Gy12,17,22 or the V27 must
e inferior to 0.5 cc.28
.  Conclusion
onsidering the volume of data accumulated for the last
wenty years concerning liver SBRT, this treatment appears
o more  as promising or experimental. The articles analyzed
ere show that it takes its place as a routine treatment among
trategies of destruction of oligo metastases, as radiofre-
uency and surgery, in a curative intent. For treating primary
epatic tumors, SBRT is also an efficient alternative to local
urgery, or chemo-embolization. Using strict criteria to protect
ealthy organs, SBRT associated with IGRT offers a high thera-
eutic index at least comparable to other ablative treatments.
s a noninvasive approach it offers the opportunity of deliver-
ng iterative treatments in association with drug treatments,
f necessary, leading to consider hepatic primary or secondary
umors as a chronic disease with the preservation of a good
uality of life.
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